{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:50Z","timestamp":1790812730314,"version":"4.1.0"},"reference-count":75,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["148522"],"award-info":[{"award-number":["148522"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN\u2010143270"],"award-info":[{"award-number":["FDN\u2010143270"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002879","name":"Canadian HIV Trials Network, Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CTN\u2010222"],"award-info":[{"award-number":["CTN\u2010222"]}],"id":[{"id":"10.13039\/501100002879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Intern AIDS Soc"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>There is currently no published data on the effectiveness of <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> treatment for elimination of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected populations at a population level. However, a number of relevant studies and initiatives are emerging. This research aims to report cascade of care data for emerging <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> elimination initiatives and studies that are currently being evaluated in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> co\u2010infected populations in the context of implementation science theory.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> elimination initiatives and studies in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> co\u2010infected populations that are currently underway were identified. Context, intervention characteristics and cascade of care data were synthesized in the context of implementation science frameworks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> elimination initiatives and studies were identified in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> co\u2010infected populations, mainly operating in high\u2010income countries. Four were focused mainly on <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> elimination in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected gay and bisexual men (<jats:styled-content style=\"fixed-case\">GBM<\/jats:styled-content>), and three included a combination of people who inject drugs (<jats:styled-content style=\"fixed-case\">PWID<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">GBM<\/jats:styled-content> and other <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected populations. None were evaluating treatment delivery in incarcerated populations. Overall, <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> was detected in 4894 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected participants (range within studies: 297 to 994): 48% of these initiated <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment (range: 21% to 85%; within studies from a period where <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s were broadly available the total is 57%, range: 36% to 74%). Among studies with treatment completion data, 96% of 1109 initiating treatment completed treatment (range: 94% to 99%). Among those who could be assessed for sustained virological response at 12\u00a0weeks (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12), 1631 of 1757 attained <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 (93%, range: 86% to 98%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Early results from emerging research on <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> elimination in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected populations suggest that <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment uptake is higher than reported levels prior to <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> treatment availability, but approximately half of patients remain untreated. These results are among diagnosed populations and additional effort is required to increase diagnosis rates. Among those who have initiated treatment, completion and <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates are promising. More data are required in order to evaluate the effectiveness of these elimination programmes in the long term, assess which intervention components are effective, and whether they need to be tailored to particular population groups.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jia2.25051","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T07:27:59Z","timestamp":1523345279000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Linkage and retention in <scp>HCV<\/scp> care for <scp>HIV<\/scp>\u2010infected populations: early data from the <scp>DAA<\/scp> era"],"prefix":"10.1002","volume":"21","author":[{"given":"Rachel","family":"Sacks\u2010Davis","sequence":"first","affiliation":[{"name":"Disease Elimination Program Burnet Institute Melbourne Australia"},{"name":"Department of Medicine The University of Melbourne Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S","family":"Doyle","sequence":"additional","affiliation":[{"name":"Disease Elimination Program Burnet Institute Melbourne Australia"},{"name":"Department of Infectious Diseases The Alfred and Monash University Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases University Hospital and University of Bern Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Beguelin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases University Hospital and University of Bern Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa E","family":"Pedrana","sequence":"additional","affiliation":[{"name":"Disease Elimination Program Burnet Institute Melbourne Australia"},{"name":"Department of Epidemiology and Preventive Medicine Monash University Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Kirby Institute University of New South Wales Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[{"name":"Public Health Service Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"van der Valk","sequence":"additional","affiliation":[{"name":"International Antiviral Therapy Evaluation Center and Department of Infectious Diseases Tropical Medicine and AIDS Academic Medical Centre Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina B","family":"Klein","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Chronic Viral Illness Service McGill University Health Centre Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Saeed","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health McGill University Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Infectious Diseases, AP\u2010HP Sorbonne Universit\u00e9s and Inserm UMR\u2010S1136 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoloz","family":"Chkhartishvili","sequence":"additional","affiliation":[{"name":"Infectious Diseases AIDS and Clinical Immunology Research Center Tbilisi Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L","family":"Altice","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases Yale School of Medicine New Haven CT USA"},{"name":"Epidemiology of Microbial Diseases Yale School of Public Health New Haven CT USA"},{"name":"Centre of Excellence in Research in AIDS University of Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E","family":"Hellard","sequence":"additional","affiliation":[{"name":"Disease Elimination Program Burnet Institute Melbourne Australia"},{"name":"Department of Epidemiology and Preventive Medicine Monash University Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00485-5"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60604-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja12.10556"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462416651229"},{"issue":"10049","key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","article-title":"Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees","volume":"388","author":"Dolan K","journal-title":"Lancet"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04419.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit296"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw075"},{"key":"e_1_2_9_10_1","unstructured":"World Health Organization.Global Health Sector Stratgy on Viral Hepatitis 2016\u20102021. Towards Ending Viral Hepatitis.Geneva Switzerland;2016."},{"issue":"4","key":"e_1_2_9_11_1","first-page":"310","article-title":"Hepatitis C virus: a review of treatment guidelines, cost\u2010effectiveness, and access to therapy","volume":"4","author":"Lynch SM","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000216"},{"key":"e_1_2_9_13_1","unstructured":"UNAIDS.Global AIDS update 2016.Geneva Switzerland:2016."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit326"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.08.035"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60232-2"},{"issue":"1","key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"ofw219","DOI":"10.1093\/ofid\/ofw219","article-title":"Physician decisions to defer antiretroviral therapy in key populations: implications for reducing human immunodeficiency virus incidence and mortality in Malaysia","volume":"4","author":"Ferro EG","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-016-0398-2"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/chp.1340240506"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-10-7"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2014.08.014"},{"issue":"4","key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"19507","DOI":"10.7448\/IAS.17.4.19507","article-title":"Large disparities in HIV treatment cascades between eight European and high\u2010income countries \u2013 analysis of break points","volume":"17","author":"Raymond A","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000878"},{"key":"e_1_2_9_25_1","volume-title":"HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2017","author":"Kirby Institute","year":"2017"},{"key":"e_1_2_9_26_1","volume-title":"Summary: Measuring Canada's Progress on the 90\u201090\u201090 HIV Targets","author":"Public Health Agency of Canada","year":"2017"},{"key":"e_1_2_9_27_1","unstructured":"vanSighemAI BoenderTS WitFWNM SmitC MatserA ReissP.Monitoring Report 2017. Human Immunodeficiency Virus (HIV) Infection in the Netherlands. Amsterdam: Stichting HIV Monitoring.2017[cited 28 November 2017]. Available from:www.hiv-monitoring.nl"},{"key":"e_1_2_9_28_1","unstructured":"ChkhartishviliN AbutidzeA BolokadzeN ChokoshviliO DvaliN SharvadzeL et\u00a0al.Hepatitis C Care Cascade for People Living With HIV in the Country of Georgia. IAS 2017;Paris France;2017."},{"key":"e_1_2_9_29_1","volume-title":"Co\u2010infection: HIV & Viral Hepatitis a guide for clinical management","author":"Cowie B","year":"2010"},{"issue":"22","key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"18888","DOI":"10.2807\/ese.13.22.18888-en","article-title":"Prevalence of hepatitis C and hepatitis B infection in the HIV\u2010infected population of France, 2004","volume":"13","author":"Larsen C","year":"2008","journal-title":"Eurosurveillance"},{"key":"e_1_2_9_31_1","unstructured":"Swiss HIV Cohort Study & Swiss Mother and Child HIV Cohort Study: Hepatitis C[cited 2017 14 November]. Available from:http:\/\/www.shcs.ch\/281-6-hepatitis-c"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4385643"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30373-X"},{"key":"e_1_2_9_34_1","unstructured":"International Lesbian G Bisexual Trans and Intersex Association: Carroll A. Itaborahy LP.State Sponsored Homophobia 2015: A world survey of laws: criminalisation protection and recognition of same\u2010sex loveGeneva: ILGA 2015 May."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20160008"},{"key":"e_1_2_9_36_1","unstructured":"British Columbia Centre for Excellence in HIV\/AIDS. Targeted disease elimination [cited 27 June 2017 ]. Available from:http:\/\/www.cfenet.ubc.ca\/research\/epidemiology-population-health\/hepatitis-c-research-program\/targeted-disease-elimination"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12247"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12371"},{"key":"e_1_2_9_39_1","first-page":"224","article-title":"Estimation de la pr\u00e9valence de l'h\u00e9patite C en population g\u00e9n\u00e9rale, France m\u00e9tropolitaine, 2011","volume":"13","author":"Pioche C","year":"2016","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13453"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyp297"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133232"},{"key":"e_1_2_9_43_1","first-page":"1","article-title":"Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study","volume":"00","author":"B\u00e9guelin C","year":"2017","journal-title":"Liver Int"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25013"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30329-0"},{"key":"e_1_2_9_46_1","article-title":"High treatment uptake in HIV\/HCV\u2010coinfected patients after unrestricted access to direct\u2010acting antivirals in the Netherlands","author":"Boerekamps A","year":"2017","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001566"},{"key":"e_1_2_9_48_1","doi-asserted-by":"crossref","unstructured":"MartinelloM DoreGJ BopageRI FinlaysonR BakerD BlochM et\u00a0al. editors.DAA treatment scale\u2010up in HIV\/HCV co\u2010infection: characterising a population at risk for reinfection. International Liver Congree (EASL);2017April; Amsterdam.","DOI":"10.1016\/S0168-8278(17)31388-0"},{"key":"e_1_2_9_49_1","unstructured":"SalmonD.Retour d'exp\u00e9rience Cohorte ANRS CO13. Foie et VIH 9 Nov; Rencontres Sainte Marguerite Marseille France;2017."},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw379"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30208-0"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1007"},{"key":"e_1_2_9_53_1","unstructured":"World Health Organization.Global hepatitis report 2017.Geneva;2017."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.02.018"},{"issue":"4","key":"e_1_2_9_55_1","first-page":"235","article-title":"A survey of hepatitis C management by Victorian GPs after PBS\u2010listing of direct\u2010acting antiviral therapy","volume":"46","author":"Wade A","year":"2017","journal-title":"Aust Fam Physician"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087564"},{"key":"e_1_2_9_57_1","unstructured":"CaceresC PechenyM FrascaT Raupp RiosR.Review of Legal Frameworks and the Situation of Human Rights related to Sexual Diversity in Low and Middle Income Countries. Report commissioned by UNAIDS 2008."},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30073-5"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60832-X"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30466-4"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.008"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06295.x"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.054"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.05.001"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.100"},{"key":"e_1_2_9_66_1","doi-asserted-by":"crossref","unstructured":"LitwinAH AgyemangL AkiyamaMJ NortonBL HeoM NingY et\u00a0al.The PREVAIL study: intensive models of HCV care for people who inject drugs.Jersey City USA:INHSU;2017.","DOI":"10.1016\/S0168-8278(17)30406-3"},{"key":"e_1_2_9_67_1","unstructured":"BoyleA MarraF FoxR FlemingC ReillyE HeydtmannM et\u00a0al.Successful treatment of patients on opiate replacement therapy utilising partial directly observed therapy of DAAs in community pharmacies.Jersey City USA:INHSU;2017."},{"key":"e_1_2_9_68_1","unstructured":"ValenteR SousaM NunesJ GomesC GouveiaC FerreiraAM.Hepatitis C treatment in people receiving opiod substitution therapy: a difficult population?Jersey City USA:INHSU;2017."},{"key":"e_1_2_9_69_1","unstructured":"ThierfelderC GotthardtF HuberC JochumA.High DAA\u2010treatment uptake and success in clients with chronic HCV\u2010infection under OST despite structural and individual challenges.Jersey City USA:INHSU;2017."},{"key":"e_1_2_9_70_1","unstructured":"UlsteinK BackeO MidgardH VenneslandK WusthoffL DarlgardO.Feasability and efficacy of direct\u2010acting antiviral hepatitis C treatment in a low threshold setting.Jersey City USA:INHSU;2017."},{"key":"e_1_2_9_71_1","unstructured":"RobertJ TremblayJ BissonnetH ZeagmanT LatourE.Linking PWUD to hepatitis C care and prevention.Jersey City USA:INHSU;2017."},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28769"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834bac44"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ948"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001522"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.02.006"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjia2.25051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T23:33:11Z","timestamp":1694647991000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":75,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/jia2.25051"],"URL":"https:\/\/doi.org\/10.1002\/jia2.25051","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"2017-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e25051"}}